EC Pulmonology and Respiratory Medicine

The modern concept of acute pneumonia is formed on the principle of the dominant role of the pathogen in the occurrence and development of the disease, and targeted etiotropic therapy continues to be considered as the only true path to success. The decrease in the effectiveness of antibiotics as a result of the development of microbial resistance, the constant dynamics of etiology, dissatisfaction with the results of emergency bacteriological diagnostics and the desire to increase the effectiveness of antimicrobial therapy have given rise to a tendency to classify the disease depending on the conditions of its occurrence, suggesting infection with various pathogens depending on the situation. The lack of convincing practical achievements in this case is another argument for revising such narrowly selective ideas about the nature of the disease, and the steady growth of viral forms in recent years is an incentive to accelerate this process. The essence of this classification may be of interest to statisticians, but does not have a significant impact on clinical results.

 Keywords: Acute Nonspecific Inflammation in the Lungs; Acute Pneumonia; Etiology; Classification; Pathogenesis; Conception of Disease

1. Gram C. "Über die isolierte Färbung der Schizomyceten in Schnitt- und Trocken-präparaten". Fortschritte der Medizin 6 (1884): 185-189.
2. Aminov RI. "A brief history of the antibiotic era: lessons learned and challenges for the future". Frontiers in Microbiology 1 (2010): 134.
3. Llitjos JF., et al. “Increased susceptibility to intensive care unit-acquired pneumonia in severe COVID-19 patients: a multicentre retrospective cohort study”. Annals of Intensive Care 1 (2021): 20.
4. J Johnstone., et al. “Definitions, rates and associated mortality of ICU-acquired pneumonia: A multicenter cohort study”. Journal of Critical Care 75 (2023): 154284.
5. Kristin R Wise., et al. “Increased long-term mortality in patients admitted to the intensive care unit with health-care associated pneumonia”. medRxiv (2021): 2021.12.23.21267010.
6. Lakbar I., et al. “Association between mortality and highly antimicrobial-resistant bacteria in intensive care unit-acquired pneumonia”. Scientific Reports 11 (2021): 16497.
7. Lee YH., et al. “Risk factors for mortality in intensive care unit patients with Stenotrophomonas maltophilia pneumonia in South Korea”. Acute and Critical Care 4 (2023): 442-451.
8. C Heneghan., et al. “Differentiating viral from bacterial pneumonia”. The Centre for Evidence-Based Medicine. Evidence Service to support the COVID-19 response. University of Oxford (2020).
9. Kamat IS., et al. “Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis”. Clinical Infectious Diseases 3 (2020): 538-542.
10. Lhommet C., et al. “Predicting the microbial cause of community-acquired pneumonia: can physicians or a data-driven method differentiate viral from bacterial pneumonia at patient presentation?” BMC Pulmonary Medicine 1 (2020): 62.
11. Zheng YY., et al. “COVID‐19 and the cardiovascular system”. Nature Reviews Cardiology 5 (2020): 259-260.
12. Oran DP and Topol EJ. “Prevalence of asymptomatic SARS‐CoV‐2 infection”. Annals of Internal Medicine 5 (2020): 362-367.
13. Wu Z and McGoogan JM. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention”. Journal of the American Medical Association 13 (2020): 1239-1242.
14. The American Thoracic Society (ATS) 2023 International Conference”. Washington, D.C., USA, in May 2023. Respiratory AMJ1 (2023): 26-35.
15. Pratik Sinha. “Severe viral lower respiratory tract infections pose a significant burden on patients and healthcare systems”. Respiratory AMJ1 (2023): 26-35.
16. Nuala Meyer. “Dysregulated host immune response is the driver of disease progression and severe patient outcomes”. Respiratory AMJ 1 (2023): 26-35.
17. Cao L., et al. “Epidemiology and mortality predictors for severe childhood community-acquired pneumonia in ICUs: A retrospective observational study”. Frontiers in Pediatrics 11 (2023): 1031423.
18. Pierre-François Daquan., et al. “Hydrocortisone in severe community-acquired pneumonia”. New England Journal of Medicine 21 (2023): 1931-1941.
19. Martin-Loeches I., et al. “ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia”. Intensive Care Medicine 6 (2023): 615-632.
20. Alex R Schuurman., et al. “The host response in different aetiologies of community-acquired pneumonia”. The Lancet, Discovery Science 81 (2022): 104082.
21. Jeremy Hsu. “AI discovers new class of antibiotics to kill resistant bacteria”. New Scientist3472 (2024): 12.
22. De Corte T., et al. “Characteristics of co-infection and secondary infection amongst critically ill COVID-19 patients in the first two waves of the pandemic”. Intensive Care Medicine 6 (2024): 989-993.
23. Kling K Qi., et al. “The impact of next-generation sequencing added to multiplex PCR on antibiotic stewardship in critically ill patients with suspected pneumonia”. Diagnostics13 (2024): 1388.
24. Rudan I., et al. “Epidemiology and etiology of childhood pneumonia”. Bulletin of the World Health Organization 5 (2008): 408-416.
25. WHO Revised global burden of disease 2002 estimates (2004).
26. Ruuskanen O., et al. "Viral pneumonia". Lancet9773 (2011): 1264-1275.